A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment

• Published in: Neuropsychopharmacology (New York, N.Y.) Vol. 30; no. 6; pp. 1204 - 1215
• Main Authors: Thal, Leon J, Ferris, Steven H, Kirby, Louis, Block, Gilbert A, Lines, Christopher R, Yuen, Eric, Assaid, Christopher, Nessly, Michael L, Norman, Barbara A, Baranak, Christine C, Reines, Scott A
• Format: Journal Article
• Language: English
• Published: New York, NY Nature Publishing 01.06.2005; Nature Publishing Group
• Subjects: Aged; Biological and medical sciences; Cognition Disorders - drug therapy; Cognition Disorders - psychology; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors - therapeutic use; Dementia - psychology; Disease Progression; Double-Blind Method; Female; Humans; Lactones - therapeutic use; Male; Medical sciences; Membrane Proteins; Neuropharmacology; Neuropsychological Tests; Pharmacology. Drug treatments; Prostaglandin-Endoperoxide Synthases - metabolism; Psychiatric Status Rating Scales; Sulfones - therapeutic use; Human; nonsteroidal anti-inflammatory drugs; Prostaglandin-endoperoxide synthase; COX-2 inhibitors; Nervous system diseases; Rofecoxib; Cognitive disorder; Enzyme; Alzheimer disease; Enzyme inhibitor; Patient; Cyclooxygenase 2 inhibitor; Cerebral disorder; Non steroidal antiinflammatory agent; Randomization; Central nervous system disease; Double blind study; Degenerative disease; mild cognitive impairment; Oxidoreductases; Alzheimer's disease

Inflammatory mechanisms have been implicated in Alzheimer's disease (AD) and might be mediated via the COX-2 enzyme. Previous studies with the selective COX-2 inhibitors, rofecoxib and celecoxib, have shown that they do not alter the progression of AD. We conducted a double-blind study to inves...